Abstract
The purpose of this investigation was to evaluate the discriminative stimulus effects of the mixed-opioid agonist/antagonist dezocine. In pigeons trained to discriminate 1.7 mg/kg dezocine from saline, a series of opioids with activity at the mu opioid receptor substituted completely for the dezocine stimulus with a rank order of potency similar to that obtained in other assays sensitive to the effects of mu agonists (i.e., fentanyl >[-]-cyclazocine >buprenorphine = butorphanol >l-methadone >nalbuphine >[-]-metazocine >morphine). (-)-N-allylnormetazocine and (+)-propoxyphene substituted partially for the dezocine stimulus, an effect obtained even when tested up to doses that suppressed responding. Naloxone (0.1 - 10 mg/kg) antagonized the stimulus effects of dezocine, (+)-propoxyphene and fentanyl in a dose-related manner, whereas doses of naloxone that antagonized fentanyl’s rate-decreasing effects failed to antagonize the rate-decreasing effects of dezocine and (+)-propoxyphene. A 10-mg/kg dose of the mu-selective, noncompetitive antagonist β-funaltrexamine was more effective against the stimulus effects of dezocine and nalbuphine than against morphine and fentanyl. As was observed with naloxone, β-funaltrexamine failed to antagonize dezocine’s rate-decreasing effects. The delta agonists BW373U86 and SNC80 substituted partially for the dezocine stimulus, and these effects were reversed by doses of the delta-selective antagonist naltrindole (0.1 and 1.0 mg/kg) that had no effect on the dezocine stimulus. Naltrindole also antagonized the rate-decreasing effects produced by BW373U86 and SNC80, but not those of dezocine. Thekappa agonists bremazocine, spiradoline, U50,488 and U69,593 failed to substitute for the dezocine stimulus. Thekappa-selective antagonist norbinaltorphimine (1.0 mg/kg) failed to antagonize dezocine’s stimulus or rate-decreasing effects. The present findings indicate that dezocine shares similar stimulus effects with both mu and deltaagonists, its stimulus effects are reversed bymu-selective antagonists, and its rate-decreasing effects are not mediated by activity at mu,kappa or delta opioid receptors.
Footnotes
-
Send reprint requests to: Dr. Mitchell J. Picker, Department of Psychology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-3270.
-
↵1 This work was supported by United States Public Service Grant DA10277 from the National Institute on Drug Abuse.
- Abbreviations:
- FR
- fixed ratio
- βFNA
- β-funaltrexamine
- nor-BNI
- norbinaltorphimine
- ED
- effective dose
- CL
- confidence limits
- Received December 24, 1996.
- Accepted July 17, 1997.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|